Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7511041 | BAYER HEALTHCARE | Fused azole-pyrimidine derivatives |
May, 2024
(14 days from now) | |
US8466283 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Oct, 2029
(5 years from now) | |
USRE46856 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
Oct, 2029
(5 years from now) | |
US10383876 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
Mar, 2032
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9636344 | BAYER HEALTHCARE | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts |
Mar, 2032
(7 years from now) |
Aliqopa is owned by Bayer Healthcare.
Aliqopa contains Copanlisib Dihydrochloride.
Aliqopa has a total of 5 drug patents out of which 0 drug patents have expired.
Aliqopa was authorised for market use on 14 September, 2017.
Aliqopa is available in powder;intravenous dosage forms.
Aliqopa can be used as treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.
Drug patent challenges can be filed against Aliqopa from 14 September, 2021.
The generics of Aliqopa are possible to be released after 29 March, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-155) | Sep 14, 2024 |
Orphan Drug Exclusivity(ODE) | Sep 14, 2024 |
New Chemical Entity Exclusivity(NCE) | Sep 14, 2022 |
Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient
NCE-1 date: 14 September, 2021
Market Authorisation Date: 14 September, 2017
Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies
Dosage: POWDER;INTRAVENOUS